ASSESSMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ASSOCIATED OBESITY AND WAYS OF ITS CORRECTION

Abstract

Objective: The aim: To analyze and calculate CVR in patients with T2DM and concomitant obesity.

Patients and methods: Materials and methods: The selection of patients was carried out based on the Uzhhorod District Clinical Hospital, in the period from November 2016 to January 2020. All patients were divided into 3 groups: 1 (n=93) with T2DM and concomitant obesity, 2 (n=87) with T2DM, 3 (n=39) with obesity. The treatment period lasted 1 year and included dosed exercise for at least 30 minutes per day and dietary recommendations. Patients in groups 1 and 2 received metformin 850 mg twice daily in combination with dapagliflozin 10 mg once daily. CVR was determined at the time of enrollment and after 1 year of treatment using: American College of Cardiology / American Heart Association Guideline on the Assessment of Cardiovascular Risk (2013) (ASCVD Risk) and Framingham Risk Score (FRS).

Results: Results: The data obtained as a result of the study revealed the highest CVR in patients of group 1, in contrast to group 2 and 3 (p<0.05). After 1 year of complex treatment, CVR indicators were statistically significantly reduced in all experimental groups (p<0.05).

Conclusion: Conclusions: Determining CVR parameters and exposure to them within 10 years can remove unwanted cardiovascular complications.

Keywords: cardiovascular risk; dapaglifloflozin; diagnostics; obesity; treatment; type 2 diabetes mellitus.